Prosecution Insights
Last updated: November 12, 2026

Harpoon Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Harpoon Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 2 distinct art units, so the portfolio spans more than one examination group while maintaining a separate examiner for each listed action.

DRISCOLL, MAUREEN VARINA is the busiest examiner, with 1 pending office action. The distribution supports tracking each matter independently and tailoring prosecution responses to the assigned examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
3
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (67%)
0
Medium (0%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting only1 (33%)
Multi-statute (no §101)2 (67%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DRISCOLL, MAUREEN VARINA 1 66.0% +40.7%
HADDAD, MAHER M 1 50.6% +53.8%
SKELDING, ZACHARY S 1 59.8% +41.3%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18635533 CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES DRISCOLL, MAUREEN VARINA —
18457177 COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS HADDAD, MAHER M —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18635533 CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES DRISCOLL, MAUREEN VARINA —
18457177 COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS HADDAD, MAHER M —
18188037 SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS SKELDING, ZACHARY S —

Top Art Units

Art UnitApps
1644 2
1641 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18635533 CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES DRISCOLL, MAUREEN VARINA 1644 §102§103§112Other Non-Final OA — Pending Apr 15, 2024
18457177 COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS HADDAD, MAHER M 1641 §102§103§112 Non-Final OA — Pending Aug 28, 2023
18188037 SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS SKELDING, ZACHARY S 1644 DP Non-Final OA — Pending Mar 22, 2023

Managing Harpoon Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Harpoon Therapeutics Inc. have?

Harpoon Therapeutics Inc. has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.

Which USPTO examiner handles the most Harpoon Therapeutics Inc. applications?

Maureen Varina Driscoll has the most, with 1 of Harpoon Therapeutics Inc.'s pending office actions.

What technology area are Harpoon Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month